share_log

Recursion Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Recursion Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Recursion Pharmaceuticals | S-8：员工福利计划证券登记
美股SEC公告 ·  05/10 15:06
Moomoo AI 已提取核心信息
Recursion Pharmaceuticals, Inc., a biotechnology firm incorporated in Delaware, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission (SEC) on May 10, 2024. This filing pertains to the registration of additional shares of Class A common stock under the company's 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan. The registration builds upon previous filings made on April 16, 2021, May 10, 2022, and May 8, 2023. The company, which is classified as a large accelerated filer, has incorporated by reference its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and subsequent reports filed with the SEC. The documents incorporated by reference include detailed information about the company's financial performance and governance. The CEO, Christopher Gibson, along with other executives and directors, have signed the registration statement, affirming the company's compliance with the requirements for filing on Form S-8.
Recursion Pharmaceuticals, Inc., a biotechnology firm incorporated in Delaware, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission (SEC) on May 10, 2024. This filing pertains to the registration of additional shares of Class A common stock under the company's 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan. The registration builds upon previous filings made on April 16, 2021, May 10, 2022, and May 8, 2023. The company, which is classified as a large accelerated filer, has incorporated by reference its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and subsequent reports filed with the SEC. The documents incorporated by reference include detailed information about the company's financial performance and governance. The CEO, Christopher Gibson, along with other executives and directors, have signed the registration statement, affirming the company's compliance with the requirements for filing on Form S-8.
在特拉华州注册的生物技术公司Recursion Pharmicals, Inc. 已于2024年5月10日向美国证券交易委员会（SEC）提交了S-8表格的注册声明。该文件涉及根据公司2021年股权激励计划和2021年员工股票购买计划注册额外A类普通股。该注册建立在先前于2021年4月16日、2022年5月10日和2023年5月8日提交的申请基础上。该公司被列为大型加速申报人，已以引用方式纳入了截至2023年12月31日财年的10-K表年度报告以及随后向美国证券交易委员会提交的报告。以引用方式纳入的文件包括有关公司财务业绩和治理的详细信息。首席执行官克里斯托弗·吉布森以及其他高管和董事签署了注册声明，确认公司遵守了提交S-8表格的要求。
在特拉华州注册的生物技术公司Recursion Pharmicals, Inc. 已于2024年5月10日向美国证券交易委员会（SEC）提交了S-8表格的注册声明。该文件涉及根据公司2021年股权激励计划和2021年员工股票购买计划注册额外A类普通股。该注册建立在先前于2021年4月16日、2022年5月10日和2023年5月8日提交的申请基础上。该公司被列为大型加速申报人，已以引用方式纳入了截至2023年12月31日财年的10-K表年度报告以及随后向美国证券交易委员会提交的报告。以引用方式纳入的文件包括有关公司财务业绩和治理的详细信息。首席执行官克里斯托弗·吉布森以及其他高管和董事签署了注册声明，确认公司遵守了提交S-8表格的要求。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息